{Reference Type}: Journal Article
{Title}: Production of a chimeric porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine using a lab-scale packed-bed bioreactor CelCradle.
{Author}: Choi HY;Choi JC;Kang YL;Ahn SH;Lee SW;Park SY;Song CS;Choi IS;Lee JB;
{Journal}: BMC Vet Res
{Volume}: 19
{Issue}: 1
{Year}: 2023 Aug 2
{Factor}: 2.792
{DOI}: 10.1186/s12917-023-03659-4
{Abstract}: <B>BACKGROUND: </B>We developed a MARC-145 cell culture and porcine reproductive and respiratory syndrome (PRRS) vaccine production using a novel CelCradle bioreactor. CelCradle is a packed-bed bioreactor capable of both batch and perfusion culture, and the operating parameters are easy to optimize.<BR><B>RESULTS: </B>In this study, CelCradle reached a maximum cell density of 8.94 × 105 cells/mL at 5 days post-seeding when seeded at 8.60 × 104 cells/mL (doubling time = 35.52 h). Inoculation of PRRS vaccine candidate, K418DM1.1, was performed at a multiplicity of infection (MOI) of 0.01 at 5 days post-seeding, which resulted in a high viral titer of 2.04 × 108 TCID50/mL and total viral load of 1.02 × 1011 TCID50/500 mL at 2 days post-infection (dpi). The multilayer cultivation system, BioFactory culture, yielded a higher doubling time (37.14 h) and lower viral titer (i.e., 8.15 × 107 TCID50/mL) compared to the CelCradle culture. Thus, the culture medium productivity of the CelCradle culture was 2-fold higher than that of the BioFactory culture. In the animal experiment, the CelCradle-produced vaccine induced high levels of neutralizing antibodies and effectively protected pigs against homologous challenge, as shown by the significantly lower levels of viremia at 1- and 7-days post-challenge (dpc) compared to the non-vaccinated pigs.<BR><B>CONCLUSIONS: </B>Overall, this study demonstrates that the CelCradle system is an economical platform for PRRS vaccine production.